Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma

Published:2008-11-01 Issue:9 Volume:113 Page:2496-2503
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Derenzini Enrico,Musuraca Gerardo,Fanti Stefano,Stefoni Vittorio,Tani Monica,Alinari Lapo,Venturini Filippo,Gandolfi Letizia,Baccarani Michele,Zinzani Pier Luigi

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.23861/fullpdf

Reference21 articles.

1. Treatment of non-Hodgkin's lymphoma;Armitage;N Engl J Med.,1993

2. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffer;N Engl J Med.,2002

3. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International (Mint) Group;Pfreundschuh;Lancet Oncol.,2006

4. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive NHL;Philip;N Engl J Med.,1995

5. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma;Vose;J Clin Oncol.,1993

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Re-examining the role of hematopoietic stem cell transplantation in relapsed large B-cell lymphoma in the era of chimeric antigen receptor (CAR) T-cell therapy;Frontiers in Oncology;2024-08-15

2. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma;Blood Reviews;2024-01

3. Positron Emission Tomography Molecular Imaging for Phenotyping and Management of Lymphoma;Phenomics;2022-02-24

4. Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective;Clinical Lymphoma Myeloma and Leukemia;2021-12

5. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas;Transplantation and Cellular Therapy;2021-11